Clinical Trial

Intravenous Autologous CD19 CAR-T Cells for R/ R MM, B-ALL, and B-Cell Lymphoma

Study acronym: ECAR01
Recruiting
View on ClinicalTrials.gov →
Summary
This is an open label, single-site, dose-escalation study in up to 18 participants with Relapsed or Refractory Multiple Myeloma, Acute B-Cell Leukemia, and B-Cell Lymphoma. This study aims to evaluate the safety and efficacy of the treatment with Anti-BCMA and CD19 CART
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-05-06.
Trial Details
NCT Number NCT06961669
Lead Sponsor Anhui Provincial Hospital
Conditions Lymphoblastic Leukemia, Relapsed or Refractory Multiple Myeloma (RRMM)
Enrollment 18 participants
Start Date 2025-04-16
Primary Completion 2028-08-31 (estimated)
Study Completion 2028-08-31 (estimated)
Updated on ClinicalTrials.gov 2025-05-29